BioLamina AB

https://www.biolamina.com

LinkedIn: https://www.linkedin.com/company/biolamina-ab

BioLamina is a biotechnology company with a scientific base and heritage in matrix biology and cell culture research. It supports scientists who have struggled for decades to grow embryonic stem cells, induced pluripotent stem (iPS) cells and other primary cells. By providing tools for efficient and easy culture, BioLamina aims to ease the path towards safe and effective cell therapy. The power of Biolaminin® substrates, developed by BioLamina, has been demonstrated in numerous publications, and they will continue to provide vital support to the stem cell community - from scientific concepts to clinical studies. Based in Sundbyberg (Sweden), the company currently employs 70 people. The company’s main shareholders include Bure Equity AB (via Bure Growth), the Tryggvason family (founders), Northislet AB, and Lauxera Capital Partners. *

	Start	2009-01-01 established
	Group	BioLamina (Group)
	Industry	cell culture system
	Industry 2	Biolaminin® substrate
	Person	Sköld, Veronica Byfield (BioLamina 202308 CEO)
	Person 2	Gäreskog, Mattias (BioLamina 202309– promoted to Chief Commercial Officer fomerly at Mercodia AB)

	Region	Stockholm
	Country	Sweden
	Street	5 Löfströms Allé
	City	17266 Sundbyberg (Stockholm)
	Tel	+46-8-5888-5180
		Address record changed: 2024-01-05

Basic data	Employees	C: 51 to 100 (2023-09-12)

		* Document for »About Section«: Lauxera Capital Partners. (9/12/23). "Press Release: Lauxera Capital Partners Invests €17 Million in Swedish Regenerative Medicine Leader BioLamina AB". Paris & San Francisco, CA.

		Record changed: 2024-02-20